AIDS CLINICAL TRIALS

对于1991年的ACTG重赛，康奈尔大学的独立Actus 大学医学院和纪念斯隆-凯特琳癌症中心 (MSKCC)已选择合并为一个主要ACTU并增加两个新的亚单位， 曼哈顿的圣克莱尔医院和曼哈顿的北岸大学医院 长岛。MSKCC也在申请病毒学和药理学核心 实验室。CUMC和MSKCC Actus的合并将提供关键 有机会(A)精简和合并共同开展的反恐股活动，(B) 在保持入学人数的同时提高成本效益，以及(C)合理 在一个地点集中和指导高优先级试验，该地点有以下两种情况 公认的临床专业知识或最佳的专用临床设施。 圣克莱尔医院(东海岸最活跃的艾滋病毒单位)的增加 和北岸作为子单位将增加妇女、少数族裔、 静脉吸毒人员和囚犯将ACTG网络扩展到纽约服务不足的地区 纽约市(皇后区)和长岛，并向ACTG提供额外的 研究人员是艾滋病毒相关疾病方面的专家。 CUMC和MSKCC Actus已经为 ACTG，并在第一、第二和第三阶段取得了高水平的成就 ACTG三个优先领域的三项议定书：原发艾滋病毒感染， 机会性感染(OI)和OI试验中的肿瘤学登记，CUMC- MSKCC在纽约市排名第一，在全国排名第七，在 肿瘤学试验招生人数位居纽约市第一和第二 全国范围内。保持在其他投资和投资方面的高参与度 肿瘤学研究将是新的CUMC-MSKCC ACTU的主要目标 及其亚基。除了庞大的内源性患者群体 已经在CUMC-MSKCC ACTU的主要地点和两个子单位(两者都是 纽约州指定的艾滋病护理单位)，40多个独立的联系 也将被用作患者试验的来源，明确强调 招募任职人数不足的群体。其他特别重要的 新的CUMC-MSKCC ACTU的组件包括一个新的大型(专用) 门诊部，GCRC支持性机构，精通OI和 肿瘤学试验，一个积极的社区咨询委员会，和护理， 行政、数据管理和药房工作人员经验丰富 在ACTG临床试验中发挥作用。CUMC-MSKCC及其亚基 为开展高优先级的ACTG研究提供独特的ACTU。

For the 1991 ACTG recompetition, the independent ACTUs at Cornell University Medica College (CUMC) and Memorial Sloan-Kettering Cancer Center (MSKCC) have elected to merge as one Main ACTU and add two new Subunits, St. Clare's Hospital in Manhattan and North Shore University Hospital on Long Island. MSKCC is also applying for Virology and Pharmacology Core Laboratories. The merger of the CUMC and MSKCC ACTUs will provide the key opportunities to (a) streamline and consolidate shared ACTU activities, (b) increase cost efficiency while maintaining enrollment, and (c) rationally focus and direct high priority trials at one site which has either recognized clinical expertise or an optimal dedicated clinical facility. The addition of St. Clare's (the most active HIV Unit on the East Coast) and North Shore as Subunits will enhance accrual of women, minorities, IVDUs, and prisoners, extend the ACTG network to underserved areas of New York City (Queens) and Long Island, and provide the ACTG with additional investigators expert in HIV-related disease. The CUMC and MSKCC ACTUs have made clear scientific contributions to the ACTG, and have demonstrated high-level accomplishments in phase I, II, and III protocols in three ACTG priority areas: Primary HIV Infection, Opportunistic Infections (OI), and Oncology in OI trials enrollment, CUMC- MSKCC together ranks first in New York City and seventh nationally, and in Oncology trials enrollment ranks first in New York City and second nationally. Maintaining this high level of participation in OI and Oncology studies will be the primary objective of the new CUMC-MSKCC ACTU and its Subunits. In addition to the large endogenous patient populations already at the Main CUMC-MSKCC ACTU sites and the two Subunits (both are New York State Designated AIDS Care Units), more than 40 separate linkages will also be used as sources of trials patients with clear emphasis on recruitment of under-represented groups. Other particularly important components of the new CUMC-MSKCC ACTU include a new large (dedicated) outpatient unit, a supportive GCRC, investigators skilled in OI and Oncology trials, an active Community Advisory Board, and nursing, administrative, data management, and pharmacy staffs thoroughly experienced in ACTG clinical trials work. Together, CUMC-MSKCC with its Subunits provides a unique ACTU for conducting high priority ACTG studies.